Pharmaceuticals, Biotechnology and Life Sciences
− Achieved Third Quarter 2019 ONPATTRO® Global Net Product Revenues of $46.1 Million, Including Initial Sales in Japan, with Over…
Publication describes favorable safety profile and efficacy in neurologic and other disease features in individual NPC patients following intravenous administration…
– Strong total revenue of $4.5 billion, increased 16% Y/Y driven by volume – INREBIC® (fedratinib) granted FDA approval in…
– Application supported by positive results from two global Phase 3 studies in people with cystic fibrosis ages 12 and…
Successful conclusion of an End of Phase II meeting with the FDA PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE MKT:…
Highly statistically significant activity relative to vehicle across every assessed symptom and sign observed in allergen chamber clinical trial Agreement…
Analyses of tebentafusp data provide further insight into platform’s mechanism of action, potential link to clinical activity in uveal melanoma…
BRISBANE, Calif.–(BUSINESS WIRE)–Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced it will…
– Total revenue of $131 million, driven primarily by LINZESS® (linaclotide) U.S. collaboration revenue of $85 million and ex-U.S. license…
Accelerated approvals of new biologics will drive market growth in North America LONDON–(BUSINESS WIRE)–#AmgenInc–Technavio’s report on the cancer biologics market…